Fosamax (alendronate) to be promoted to PREVENT osteoporosis in postmenopausal women

April 1997

The FDA will soon allow Fosamax (alendronate) to be promoted to prevent osteoporosis in postmenopausal women.

So far it's approved only for treatment.

Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

IMPROVING QUALITY
Dermatology Tazorac (tazarotene), a new topical retinoid gel
Dermatology Proscar (finasteride) stimulating hair growth
Osteoporosis Fosamax (alendronate) to be promoted to PREVENT osteoporosis in postmenopausal women
Osteoporosis New drug to inhibit bone loss called Skelid (SKEL-id, tiludronate)
Cardiology Whether digoxin really is useful for patients with heart failure
Cardiology Cozaar (losartan) for heart failure
Cardiology New drug for hypertension, Diovan (valsartan)
Gastroenterology New acid blocker called Pantoloc (pantoprazole)
Infectious Diseases New quinolone antibiotic called Zagam (sparfloxacin)
Infectious Diseases New SINGLE dose antibiotic for bladder infections, Monurol (fosfomycin)
Infectious Diseases Viracept (nelfinavir) for treating HIV in both children and adults
Anticoagulants Monitor their warfarin therapy at HOME
Asthma New asthma guidelines
Asthma Too many asthmatics still AREN'T using inhaled steroids
Cholesterol Now marketing Lipitor (atorvastatin)
Cholesterol Cholestin, a new dietary supplement to lower cholesterol
Interactions Drugs that interact with grapefruit